Niowave has signed a supply agreement with Ratio Therapeutics for current good manufacturing practice Actinium-225.
The agreement will support Ratio’s targeted radiotherapeutics pipeline, including ongoing clinical trial activities and future program advancement.
Actinium-225 is an alpha-emitting radioisotope used in targeted alpha-therapy development. The isotope can be attached to targeting molecules intended to deliver radiation to cancer cells.
The companies did not disclose financial terms, volume commitments, or the duration of the supply agreement.
Companies:Niowave, Ratio Therapeutics
Ratio Therapeutics coverage
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
